Bioadaptives Financials
This page shows Bioadaptives (BDPT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Bioadaptives passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Bioadaptives generates $0.28 in operating cash flow (-$250K OCF vs -$899K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Bioadaptives earns $-6.5 in operating income for every $1 of interest expense (-$602K vs $92K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Bioadaptives generated $13K in revenue in fiscal year 2024. This represents a decrease of 55.6% from the prior year.
Bioadaptives reported -$899K in net income in fiscal year 2024. This represents a decrease of 26.2% from the prior year.
Cash & Balance Sheet
Bioadaptives held $262K in cash against $0 in long-term debt as of fiscal year 2024.
Bioadaptives had 1.23B shares outstanding in fiscal year 2024. This represents an increase of 20526.0% from the prior year.
Margins & Returns
Bioadaptives's gross margin was 31.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 6.1 percentage points from the prior year.
Bioadaptives's operating margin was -4752.5% in fiscal year 2024, reflecting core business profitability. This is down 3951.1 percentage points from the prior year.
Bioadaptives's net profit margin was -7097.3% in fiscal year 2024, showing the share of revenue converted to profit. This is down 4603.1 percentage points from the prior year.
Capital Allocation
BDPT Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5K+43.9% | $3K | $0 | N/A | $0-100.0% | $675-94.4% | $12K+66.6% | $7K |
| Cost of Revenue | $781-63.8% | $2K | $0 | N/A | $0-100.0% | $246-97.1% | $8K+86.4% | $5K |
| Gross Profit | $4K+262.3% | $1K | $0 | N/A | $0-100.0% | $429-88.1% | $4K+33.4% | $3K |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $251K+26.8% | $198K+38.0% | $143K | N/A | $40K+774.9% | $5K-85.4% | $32K-23.2% | $41K |
| Operating Income | -$266K+4.8% | -$279K-12.1% | -$249K | N/A | -$122K-31.2% | -$93K-86.6% | -$50K+19.3% | -$62K |
| Interest Expense | $14K+46.7% | $10K0.0% | $10K | N/A | $10K-46.0% | $18K-67.1% | $55K+40.2% | $39K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$380K-140.3% | -$158K+19.9% | -$197K | N/A | -$38K+79.4% | -$183K+40.3% | -$307K-14.3% | -$268K |
| EPS (Diluted) | $-0.04-300.0% | $0.02+200.0% | $-0.02 | N/A | $0.00-100.0% | $0.06+250.0% | $-0.04 | N/A |
BDPT Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $124K-54.4% | $273K+146.7% | $110K-57.8% | $262K+464.5% | $46K+431.1% | $9K-85.1% | $59K-43.6% | $104K |
| Current Assets | $109K-57.4% | $256K+131.3% | $110K-57.8% | $262K+464.5% | $46K+431.1% | $9K-78.5% | $41K-54.1% | $89K |
| Cash & Equivalents | $59K-71.9% | $211K+432.3% | $40K-84.9% | $262K+496.6% | $44K+18577.9% | $235-98.8% | $20K-77.9% | $89K |
| Inventory | $44K+11.8% | $40K-2.5% | $41K+112.3% | $19K | $0-100.0% | $6K-67.7% | $19K+21.5% | $15K |
| Accounts Receivable | $590.0% | $59 | N/A | $0 | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.6M+5.7% | $1.5M-10.6% | $1.7M-2.6% | $1.7M-6.8% | $1.9M-1.3% | $1.9M+1.1% | $1.9M+6.1% | $1.8M |
| Current Liabilities | $1.6M+12.9% | $1.4M-16.3% | $1.7M-2.6% | $1.7M-6.8% | $1.9M-4.1% | $1.9M+4.0% | $1.9M+6.1% | $1.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$1.5M-19.0% | -$1.2M+21.6% | -$1.6M-7.3% | -$1.5M+18.9% | -$1.8M+3.3% | -$1.9M-3.9% | -$1.8M-9.2% | -$1.6M |
| Retained Earnings | -$9.9M-4.0% | -$9.5M-1.7% | -$9.4M-2.2% | -$9.2M-4.2% | -$8.8M-0.4% | -$8.8M-2.1% | -$8.6M-3.7% | -$8.3M |
BDPT Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$151K-36.3% | -$111K-13.4% | -$98K+2.6% | -$101K-78.4% | -$56K-9.5% | -$51K-25.0% | -$41K+54.9% | -$91K |
| Capital Expenditures | $0 | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| Free Cash Flow | -$151K | N/A | N/A | N/A | -$56K | N/A | N/A | N/A |
| Investing Cash Flow | $0 | N/A | N/A | N/A | $0 | N/A | N/A | N/A |
| Financing Cash Flow | $0 | N/A | N/A | $194K+94.1% | $100K | N/A | N/A | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BDPT Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.1%+50.1pp | 33.0% | N/A | N/A | N/A | 63.6%+33.5pp | 30.0%-7.5pp | 37.5% |
| Operating Margin | -5735.9%+2938.1pp | -8674.1% | N/A | N/A | N/A | -13774.5%-13359.1pp | -415.5%+442.5pp | -858.0% |
| Net Margin | -8193.0%-3287.4pp | -4905.7% | N/A | N/A | N/A | -27113.6%-24556.5pp | -2557.2%+1168.7pp | -3725.9% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -305.2%-247.2pp | -58.0%+120.5pp | -178.5% | N/A | -81.2%+2014.1pp | -2095.2%-1572.4pp | -522.8%-264.8pp | -258.0% |
| Current Ratio | 0.07-0.1 | 0.18+0.1 | 0.07-0.1 | 0.15+0.1 | 0.03+0.0 | 0.00-0.0 | 0.02-0.0 | 0.05 |
| Debt-to-Equity | -1.08+0.1 | -1.22-0.2 | -1.07+0.1 | -1.18-0.2 | -1.03-0.0 | -1.00+0.0 | -1.03+0.0 | -1.06 |
| FCF Margin | -3266.6% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$1.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.15), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Bioadaptives's annual revenue?
Bioadaptives (BDPT) reported $13K in total revenue for fiscal year 2024. This represents a -55.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bioadaptives's revenue growing?
Bioadaptives (BDPT) revenue declined by 55.6% year-over-year, from $29K to $13K in fiscal year 2024.
Is Bioadaptives profitable?
No, Bioadaptives (BDPT) reported a net income of -$899K in fiscal year 2024, with a net profit margin of -7097.3%.
What is Bioadaptives's gross margin?
Bioadaptives (BDPT) had a gross margin of 31.8% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Bioadaptives's operating margin?
Bioadaptives (BDPT) had an operating margin of -4752.5% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Bioadaptives's net profit margin?
Bioadaptives (BDPT) had a net profit margin of -7097.3% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Bioadaptives's operating cash flow?
Bioadaptives (BDPT) generated -$250K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Bioadaptives's total assets?
Bioadaptives (BDPT) had $262K in total assets as of fiscal year 2024, including both current and long-term assets.
What is Bioadaptives's current ratio?
Bioadaptives (BDPT) had a current ratio of 0.15 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Bioadaptives's debt-to-equity ratio?
Bioadaptives (BDPT) had a debt-to-equity ratio of -1.18 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bioadaptives's return on assets (ROA)?
Bioadaptives (BDPT) had a return on assets of -343.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Bioadaptives's cash runway?
Based on fiscal year 2024 data, Bioadaptives (BDPT) had $262K in cash against an annual operating cash burn of $250K. This gives an estimated cash runway of approximately 13 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Bioadaptives's debt-to-equity ratio negative or unusual?
Bioadaptives (BDPT) has negative shareholder equity of -$1.5M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Bioadaptives's Piotroski F-Score?
Bioadaptives (BDPT) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bioadaptives's earnings high quality?
Bioadaptives (BDPT) has an earnings quality ratio of 0.28x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Bioadaptives cover its interest payments?
Bioadaptives (BDPT) has an interest coverage ratio of -6.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.